Goodwin Charles D. II 4

What Happened
Charles D. Goodwin II, CEO of Apyx Medical Corp (APYX), received a grant of derivative securities on 2026-06-11 covering 213,948 shares. The Form 4 reports the acquisition price as $0.00 (an option/award), i.e., this is a compensation grant rather than an open-market purchase or sale. The award will vest ratably over a 36-month period and becomes fully vested and exercisable on the third anniversary of the grant date (see footnote).

Key Details

• Transaction date: 2026-06-11; filing date: 2026-06-15.
• Instrument: Option/award covering 213,948 shares; reported acquired at $0.00 (derivative grant).
• Vesting: Ratably over 36 months; fully vested and exercisable on the 3rd anniversary of grant (per footnote F1).
• Shares owned after transaction: not specified in the summary provided in your request.
• Timeliness: Filed four days after the transaction date (6/11 → 6/15), which is later than the typical SEC two-business-day reporting window.

Context

• This filing documents a compensation-related option grant to the CEO, not an immediate cash transaction or sale. The options do not appear to be immediately exercisable; they vest over time, meaning any potential sale or exercise would come later if and when vesting and exercising occur.
• Such grants are common for executive compensation/retention and are informational rather than a direct signal to buy or sell company stock.